GBM Clinical Trial
Official title:
A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: Stage I (Pre-screening) 1. Patients are = 20 and = 75 years of age at brain tumor resection surgery. 2. Patients with newly diagnosed single, primary, WHO grade IV, glioblastoma (except for locating on brainstem or cerebellum) scheduled to undergo craniotomy tumor excision, and are willing to preserve the resected tumor cells enabling the production of ADCV01. 3. Patients undergo tumor resection by aid of neuro-navigation without receiving any intracranial implantation therapies (e.g., BCNU wafer). 4. Only one GBM tumor number. 5. Patients must be able to understand and sign the informed consent documents and aware of the investigational nature of the study. 6. Patients have the expected life expectancy of > 12 weeks at the pre-screening visit as judged by the investigator. 7. Patients with stable vital sign and KPS = 70 at the pre-screening visit. 8. Patients with adequate renal function at the pre-screening visit: serum creatinine < 1.8 mg/dL; creatinine clearance > 30 mL/min 9. Patients with adequate liver function at the pre-screening visit: AST, ALT, and ALP = 3× upper limit of normal (ULN); and total bilirubin < 3 mg/dL 10. Patients with prothrombin time and activated partial thromboplastin time = 1.5× ULN at the pre-screening visit 11. Patients with adequate hematopoietic function at the prescreening and before administration of study medication 1. Absolute neutrophil count (ANC) = 1,000 cells/µL 2. Platelets = 100,000 counts/µL 3. Total white blood cell (WBC) = 2,000 cells/µL 4. Hemoglobin = 8 g/dL 12. All male and female patients with child-bearing potential (between puberty and 2 years after menopause) must be practicing sexual abstinence and be willing to continue to use a medically acceptable form of birth control for at least 1 month prior to screening (that period will extend to 3 months for oral contraceptive use). The patients should use appropriate contraceptive method(s) as shown below, until at least 6 months after the last dose of ADCV01 administration. 1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, thermal symptom post-ovulation methods) and withdrawal are not acceptable methods of ontraception). 2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before administration of study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. 3. Male sterilization (at least 6 months prior to screening). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject 4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3): d.1 Use of oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. 13. Patients agree to be in compliance with treatment plan as planned in the clinical protocol. Stage II (Screening/Randomization) In addition to fulfill the criteria in Stage I, following criteria should be met to be eligible for remaining in the study. 14. Patients' resected brain tumors are pathologically confirmed cases of the IDH-1 wild-type glioblastoma, and patients are willing to do monocyte-collecting apheresis at the screening/randomization visit. 15. At the screening/randomization visit, patients' resected brain tumors are confirmed of low PD-1+/ CD8+ ratio (ratio <0.21). 16. Residual tumor with less than 25% contrast-enhancing mass on post-surgical brain MRI (within 2 days post-operation) as assessed by the neurosurgeon and/or radiologist. Exclusion Criteria: Stage I (Pre-screening) 1. Number of GBM is more than one 2. Patient who has participated in other investigational studies within 4 weeks prior to pre-screening 3. Patient with known or suspected hypersensitivity to ADCV01 or its excipients 4. Patient who has a history of hypersensitivity reaction (e.g., urticarial, allergic reaction including anaphylaxis, toxic epidermal necrosis, and Stevens-Johnson syndrome) to dacarbazine (DTIC) or any components of medications of temozolomide and bevacizumab 5. Patient has acute infectious disease or acute cardiovascular disease; clinically manifest myocardial insufficiency or history of myocardial infarction during the past 6 months prior to prescreening; or has active uncontrolled arterial hypertension as supported by medical history. 6. Patient has clinically significant immuno-compromised condition (other than that related to the use of corticosteroids), is human immunodeficiency virus positive (anti-HIV and nucleic acid test) or medical condition requiring systemic immunesuppressive treatments. 7. Patient with active rheumatic disease or other collagen vascular disease, or is with active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barre syndrome). Patients with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition, only requiring hormone replacement therapy are permitted to enroll. 8. Patients with psoriasis requiring systemic therapy, or conditions expected to recur in the presence of an external trigger 9. Patient with syphilis, acute HBV, HCV (except hepatitis carriers), HTLV-I/II, CMV, or an increased risk (or has been diagnosed) for human transmissible spongiform encephalopathy (TSE); including Creutzfeldt-Jakob disease (CJD) 10. Patient with history of coagulation disorder associated with bleeding or recurrent thrombotic events 11. Patient with medical, social, or psychological factors interfering with compliance of the study 12. Female patient who is lactating, pregnant, or planned to be pregnant 13. Inability to undergo MRI for any reason 14. History of malignancy other than glioma that is not stable in the past 5 years prior to pre-screening (informed consent form signing date) 15. Patient not suitable to participate the trial as judged by the investigator. Stage II (Screening/Randomization) The patient will be no longer eligible to participate the study if he/she met any of the following criteria: 16. GBM patients with high PD-1+/CD8+ ratio = 0.21 17. GBM patients with mutant IDH-1 18. Residual tumor volume more than 25% of pre-operative tumor size. |
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | Taichung Veterans General Hospital | Taichung | Non-US |
Taiwan | Chang-Gung Memorial Hospital at Lin-Ko | Taoyuan | Non-US |
Lead Sponsor | Collaborator |
---|---|
Ever Supreme Bio Technology Co., Ltd. |
Taiwan,
Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May;16(5):696-706. doi: 10.1093/neuonc/not236. Epub 2013 Dec 12. — View Citation
Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, Chiu SC, Cho DY. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Front Immunol. 2018 May 29;9:727. doi: 10.3389/fimmu.2018.00727. eCollection 2018. — View Citation
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | One-year progression-free survival (PFS) rate | The PFS is defined as the time from randomization until the tumor objective progression or death, whichever occurs first. | the percentage of patients surviving 1 year after randomization without objective tumor progression or death. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06147505 -
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01478178 -
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
|
Phase 1/Phase 2 | |
Terminated |
NCT03119064 -
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
Recruiting |
NCT03758014 -
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01205334 -
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00114309 -
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT03746288 -
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
|
Phase 2 | |
Terminated |
NCT04681677 -
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
|
Phase 2 | |
Completed |
NCT01856933 -
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
|
Phase 2 | |
Terminated |
NCT04763031 -
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
|
N/A | |
Completed |
NCT00107003 -
GW572016 to Treat Recurrent Malignant Brain Tumors
|
Phase 2 | |
Completed |
NCT03426891 -
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT06092255 -
A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.
|
N/A | |
Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
Not yet recruiting |
NCT06388733 -
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
|
Phase 3 | |
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 |